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Eliglustat is a substrate reduction therapy approved for Gaucher
disease type-1 adult patients. We designed a prospective follow-up
post-authorization study (TRAZELGA [GEE-ELI-2017-01]) to evaluate
uniformly this therapy's response, performing a follow-up every six
months. Includes the evaluation in terms of safety and effectiveness,
analyzing clinical parameters, image bone assessment, and plasmatic
biomarkers: chitotriosidase activity was evaluated by fluorimetry,
glucosylsphingosine [GluSph] concentrations by LC-MSMS and
CCL18/PARC, C5a, C3, YKL-40, Cathepsin S, Hepcidin and Lipocalin
concentrations by inmunoassay. A quality of life study (SF-36),
disease severity score index evaluation (GD-DS3) and adverse effects
are included. Patients all over Spain, treated by Eliglustat were
included in the study. Non-parametric statistical analysis was
performed and p b 0.05 was considered as statistically significant.
At this moment, 38 patients are recruited: median age was 45.0
years, male-female ratio is 1:1, the most common genotype was
NM_000157:[c.1226A N C] + [other damaging variant] (87%).
CYP2D6 metabolizers' distribution was 3%, 9% and 88% for poor,
intermediate and normal phenotypes, respectively. Spanish MRI
score: 6.4 (0−21), T-score: −1.1 (−3,7-1,0). 13.2% patients were
splenectomized, 21.1% present multimorbidities and/or poly-
medications and, 15.8% complained fatigue as the main symptom
before their inclusion. During treatment 34% patients reported grade
1 digestive discomfort and one of them suffered a Helicobacter Pylori
infection. Two patients (5.3%) discontinued therapy due to adverse
events. 30 patients completed the first year of treatment and a
statistically significant decrease on GluSph (p= 0.0001) and an
increase on Lipocalin-2 (p = 0.01) plasmatic levels were registered
while the rest of plasmatic biomarkers maintains their values. A new
evaluation of all biomarkers, bone mineral density, response to
treatment, adherence and, adverse effects will be performed when
all patients complete the first follow-up year and will be presented at
the congress in case the paper is accepted. TRAZELGA (GZ-2017–
11,713) received a grant from Sanofi Genzyme for its realization.
doi:10.1016/j.ymgme.2020.12.239
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Novel regulatory function of GCN5L1 in lysosomal tubulation and
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Lysosomes are responsible for degradation of macromolecules
through fusion with autophagosomes and endosomes. The consumed
lysosomes are required to be regenerated through the process of
autolysosomal reformation (ALR) and lysosome biogenesis. This
project aimed to investigate the regulatory mechanism of GCN5L1
gene in lysosome tubulation (LT), a crucial step for ALR. GCN5L1
belongs to both BLOC1 and BORC multiprotein complexes and is
involved in controlling lysosomal trafficking, however, the effect of
GCN5L1 on lysosome tubulation remains largely unknown. Genetic
ablation of GCN5L1 in the liver showed a dramatic increase in
accumulation of autolysosomes, decrease in lysosome regeneration
and absence of lysosomal tubulation. This phenotype suggests the
possibility of disruption in lysosome tubulation which results in
disturbance of the overall lysosome homeostasis. Interestingly, the
genetic reintroduction of GCN5L1 rescues LT in GCN5L1 knockout
hepatocytes. To investigate if GCN5L1 regulates lysosomal compo-
nents, Lyso-IP method was used to purify lysosomes from WT and
GCN5L1−/− hepatocytes followed by quantification of lysosomal
protein expression profiles using label free LC-MS. Bioinformatic
analysis revealed that expression of lysosomal protease, Cathepsin B,
was reduced while there was a significant increase in autophagy-
related proteins in GCN5L1 −/− hepatocytes. These results support
that the autophagic flux may be blocked due to inefficient digestion
of lysosomes which results in accumulation of autolysosomes in
GCN5L1−/− hepatocytes. Consequently, the autolysosome-depen-
dent mTORC1 activity was upregulated in GCN5L1−/− hepatocytes.
Our findings suggest that GCN5L1 deficiency alters the lysosomal
signaling and contents as well as their degradation. These findings
support that GCN5L1 plays a novel regulatory role in lysosome
biology and may be involved in pathological processes of lysosome
related disease, such as storage diseases, hepatic and cardiovascular
diseases as well as the immune system function.
doi:10.1016/j.ymgme.2020.12.240
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